Abstracts Archive - Page 760 of 2607 - ACR Meeting Abstracts

Abstract Number: 0823 • ACR Convergence 2021
Pharmacokinetic and Pharmacodynamic Evaluation of a Proposed Biosimilar MSB11456 versus Both the US-licensed and EU-approved Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-dose Trial in Healthy Adults
Christian Schwabe¹, Chris Wynne², Andras Illes³, Martin Ullmann³, Emmanuelle Vincent³, Vishal Ghori³, Corinne Petit-Frere³, Anne-Sophie Racault³ and Joelle Monnet³, ¹Auckland Clinical Studies Ltd, Auckland, New Zealand, ²Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland
Background/Purpose: Tocilizumab, a biologic disease-modifying antirheumatic drug, is a recombinant humanized monoclonal immunoglobulin G1 antibody against the interleukin-6 receptor (IL-6R). MSB11456 is a proposed biosimilar…
Abstract Number: 0824 • ACR Convergence 2021
Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
Peter C Taylor¹, Bruno Fautrel², Yves Piette³, Susana Romero-Yuste⁴, Jasper Broen⁵, Martin Welcker⁶, Elizabeth Holdsworth⁷, Monia Zignani⁸, Katrien Van Beneden⁸, Roberto Caporali⁹ and Rieke Alten¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium, ⁴Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ⁵Maxima Medical Centre, Veldhoven, Netherlands, ⁶MVZ für Rheumatologie, Planegg, Germany, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Galapagos, NV, Mechelen, Belgium, ⁹Policlinico S. Matteo University, Pavia, Italy, ¹⁰Schlosspark-Klinik University, Berlin, Germany
Background/Purpose: Shared decision making, a cornerstone of rheumatoid arthritis (RA) management1, allows physicians and their patients to make informed decisions about their treatment goals and…
Abstract Number: 0825 • ACR Convergence 2021
An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial
Mikkel Ostergaard¹, Ronald van Vollenhoven², Anna Rudin³, Merete Hetland⁴, Marte S Heiberg⁵, Dan Nordström⁶, Michael Nurmohamed⁷, Bjorn Gudbjornsson⁸, Lykke Ørnbjerg⁹, Pernille Bøyesen¹⁰, Inge Olsen¹¹, Kristina Lend¹², Kim Hørslev-Petersen¹³, Till Uhlig¹⁴, Tuulikki Sokka-Isler¹⁵, Gerdur Grondal⁸, Simon Krabbe¹⁶, Joakim Lindqvist¹⁷, Inger Gjertsson¹⁸, Daniel Glinatsi⁹, Meliha Kapetanovic¹⁹, Anna-Birgitte Aga¹⁰, Francesca Faustini²⁰, Pinja Parmanne²¹, Tove Lorenzen²², Cagnotto Giovanni²³, Johan Back²⁴, Oliver Hendricks²⁵, Daisy Vedder²⁶, Tuomas Rannio²⁷, Emma Grenholm²⁸, Maud Kristine Ljoså²⁹, Eli Brodin³⁰, Hanne Merete Lindegaard³¹, Annika Söderbergh³², Milad Rizk³³, Elsa Hermansson³⁴, Per Larsson³⁵, Line Uhrenholt³⁶, Søren Andreas Just³⁷, David John Stevens³⁸, Trine Bay Laurberg³⁹, Gunnstein Bakland⁴⁰, Espen Haavardsholm⁴¹ and Jon Lampa¹⁷, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁴DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁷Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁸Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, ⁹Copenhagen Center for Arthritis Research, COPECARE, Glostrup, Denmark, ¹⁰Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ¹³King Christian X's Hospital for Rheumatic Diseases, Gråsten, Denmark, ¹⁴Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, ¹⁵University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁶Radiologisk Afdeling, Herlev Universitetshospital, Herlev, Denmark, ¹⁷Karolinska University Hospital, Stockholm, Sweden, ¹⁸Dept. of Rheumatology, Sahlgrenska University Hospital, Gothenborg, Sweden, ¹⁹Dept. of Clinical Sciences, Skåne University Hospital, Lund, Sweden, ²⁰Dept. of Medicine, Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ²¹Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ²²Dept. of Rheumatology, Silkeborg University Hospital, Silkeborg, Denmark, ²³Dept. of Clinical Sciences, Skåne University Hospital, Malmö, Sweden, ²⁴Dept. of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden, ²⁵Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²⁶Dept. of Rheumatology, Reade, Amsterdam, Netherlands, ²⁷Finland Central Hospital, Jyväskylä, Finland, ²⁸Dept. of Rheumatology, Falunl, Falun, Sweden, ²⁹Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ³⁰Dept. of Rheumatology, Haukeland University Hospital, Haukeland, Norway, ³¹Rheumatology Research Unit, Odense University Hospital, Odense, Denmark, ³²Dept. of Rheumatology, Örebro University Hospital, Örebro, Sweden, ³³Rheumatology Clinic, Västmanlands Hospital Västerås, Västerås, Sweden, ³⁴Dept. of Rheumatology, Linköping University Hospital, Linköping, Sweden, ³⁵Academic Specialist Center, Stockholm, Sweden, ³⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³⁷Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, ³⁸Dept. of Rheumatology, University Hospital of Trondheim, Trondheim, Norway, ³⁹Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴⁰Dept. of Rheumatology, University Hospital of North Norway, Tromsø, Norway, ⁴¹[email protected], Oslo, Norway
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (eRA) is yet to be established. The main objectives were to assess and…
Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
Abstract Number: 0827 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously…
Abstract Number: 0828 • ACR Convergence 2021
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
Roy Fleischmann¹, Eduardo Mysler², Louis Bessette³, Charles Peterfy⁴, Patrick DUREZ⁵, Yoshiya Tanaka⁶, Jerzy Swierkot⁷, Nasser Khan⁸, Xianwei Bu⁹, Yihan Li⁹ and In-Ho Song⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Spire Sciences, Inc., Boca Raton, FL, ⁵Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., North Chicago
Background/Purpose: In the SELECT-COMPARE study, the Janus kinase inhibitor, upadacitinib (UPA), demonstrated significant improvement in the signs and symptoms of rheumatoid arthritis (RA) when administered…
Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Line Uhrenholt¹, Robin Christensen², Wilfred K Dinesen³, Caroline Liboriussen³, Stine Andersen³, Lene Dreyer¹, Annette Schlemmer⁴, Ellen-Margrethe Hauge⁵, Conni Skrubbeltrang⁶ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ³Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, Randers Regional Hospital, Randers, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Medical Library, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…
Abstract Number: 0830 • ACR Convergence 2021
Smartphone Assisted Patient Initiated Care Safely Reduces Outpatient Clinic Visits in Patients with Rheumatoid Arthritis: Results from a Randomized Controlled Trial
Bart Seppen¹, Jimmy Wiegel¹, Marieke ter wee², DirkJan van Schaardenburg¹, Leo Roorda¹, Michael Nurmohamed³ and wouter Bos⁴, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁴Reade Amsterdam, Amsterdam, Netherlands
Background/Purpose: The demand on outpatient rheumatology clinics is high due to protocolised visits of rheumatoid arthritis (RA) patients, including those in low disease activity or…
Abstract Number: 0831 • ACR Convergence 2021
Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial
Steven R Ytterberg¹, Deepak L Bhatt², Ted Mikuls³, Gary G Koch⁴, Jose L Rivas⁵, Rebecca Germino⁶, Sujatha Menon⁶, Yanhui Sun⁷, Cunshan Wang⁶, Andrea B Shapiro⁸, Keith S Kanik⁶, Carol A Connell⁶ and Roy Fleischmann⁹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer CRDC, Shanghai, China (People's Republic), ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: ORAL Surveillance (NCT02092467) was mandated by the US Food and Drug Administration to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based…
Abstract Number: 0832 • ACR Convergence 2021
Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis
Andrea Rubbert-Roth¹, Bernard Combe², Zoltan Szekanecz³, Stephen Hall⁴, Boulos Haraoui⁵, Suzan Mansour Hussein Attar⁶, Anna-Karin Ekwall⁷, Yanna Song⁸, Tim Shaw⁹, Orsolya Nagy⁸ and Ricardo Xavier¹⁰, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²CHU Montpellier Montpellier University, Montpellier, France, ³Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ⁴Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ⁵Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁶King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁷University of Gothenburg, Gothenburg, Sweden, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., North Chicago, ¹⁰Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) across various patient populations.1–4 This post hoc analysis aimed to evaluate the…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 0834 • ACR Convergence 2021
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Anthony Sebba¹, Clifton Bingham², Vivian Bykerk³, Stefano Fiore⁴, Kerri Ford⁵, Jud C Janak⁶, Dimitrios Pappas⁶, Taylor Blachley⁶, Swapna Dave⁶, Joel Kremer⁷, Miao Yu⁶ and Ernest Choy⁸, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁸CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…
Abstract Number: 0835 • ACR Convergence 2021
Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
Jerome Avouac¹, Rodolphe Cougnaud-Murail¹, Claire Goulvestre², Sophie Dumas³, Anna Molto⁴, Corinne Miceli-Richard⁵, ornella conort³, Frederic Batteux² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Université de Paris, Service d'Immunologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ³Université de Paris, Service de pharmacie, Hôpital Cochin, AP-HP.CUP, Paris, France, ⁴Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Assistance Publique Hpitaux de PAris, Paris, France
Background/Purpose: To study in daily practice the risk of immunogenicity of patients treated with rituximab (RTX) biosimilar GP2013 for their chronic inflammatory rheumatic disorder.Methods: A…
Abstract Number: 0836 • ACR Convergence 2021
Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis
Soo Min Ahn¹, Ji Seon Oh², Hyun Mi Heo³, Seokchan Hong³, Chang-Keun Lee³, Bin Yoo¹ and Yong-Gil Kim³, ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Ulsan, Republic of Korea, ³Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Interleukin-6 (IL-6) plays a key role in inflammatory and immune responses. Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody of the IL-6 receptor which…
Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Tim Shaw⁷, Yanna Song⁶, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹Griffith University, Brisbane, Australia, ²University of California San Diego, La Jolla, CA, ³University of Leeds, Leeds, United Kingdom, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Laval University, Québec City, QC, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].